• 🧬 David Li - Meliora Therapeutics - Part 3 | Developing a Blood-Based Lung Cancer Test | The Rifle-Shot Nature of Biotech | Software Vs. Biotech Product Market Fit | The Super Power all Startups Need

  • Jul 8 2024
  • Duración: 20 m
  • Podcast

🧬 David Li - Meliora Therapeutics - Part 3 | Developing a Blood-Based Lung Cancer Test | The Rifle-Shot Nature of Biotech | Software Vs. Biotech Product Market Fit | The Super Power all Startups Need Por arte de portada

🧬 David Li - Meliora Therapeutics - Part 3 | Developing a Blood-Based Lung Cancer Test | The Rifle-Shot Nature of Biotech | Software Vs. Biotech Product Market Fit | The Super Power all Startups Need

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Part 3 of 4. My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.
    Más Menos
activate_primeday_promo_in_buybox_DT
Economía Ciencias Biológicas
Más Menos

Lo que los oyentes dicen sobre 🧬 David Li - Meliora Therapeutics - Part 3 | Developing a Blood-Based Lung Cancer Test | The Rifle-Shot Nature of Biotech | Software Vs. Biotech Product Market Fit | The Super Power all Startups Need

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles